Media OutReach
BeOne Medicines Honored with the Global Oncology Innovation Leadership Award at BIOHK 2025, Supporting “1+” to Accelerate the Delivery of Innovative Cancer Therapies
Ms. Yiya Chen, General Manager (Taiwan, Hong Kong & Macau) of BeOne, stated, “Receiving the Global Oncology Innovation Leadership Award not only affirms BeOne’s R&D capabilities, but also motivates us to accelerate the transformation of innovative breakthroughs into tangible benefits for patients in the Greater Bay Area, including Hong Kong. Currently, we offer three novel cancer therapies in Hong Kong, covering BTK inhibitor, PD-1 inhibitor, and IL-6 inhibitor. Moving forward, we will proactively leverage the opportunities under the “1+” mechanism to expedite the importation of more international-standard compliant, self-developed medicines, enabling rapid, extensive access to effective treatment for local cancer patients.
Global Research & Development Together with Powered Innovation
Since its establishment in 2010, BeOne has been upholding its mission of “Cancer has no borders. Neither do we,” focusing on developing high-quality, self-developed medicines that meet international standards, with a commitment to accessibility and affordability of innovative cancer treatments. To date, BeOne has conducted over 170 clinical trials across 45 countries and regions, building one of the world’s largest oncology research teams. More than 1.8 million patients have benefited from the achievements of its research and development.
- BTK inhibitor: BeOne’s first independently developed innovative drug, and the only treatment worldwide in its class to have completed head-to-head clinical trials in both Chronic Lymphocytic Leukemia (CLL) and Waldenström’s Macroglobulinemia (WM)1. It has been approved in more than 75 markets and was honored with the prestigious Prix Galien Suisse in 20232..
- PD-1 inhibitor (immunotherapy): Approved in Hong Kong for six indications, including non-small cell lung cancer, esophageal cancer, and gastric cancer, with expansion to nasopharyngeal carcinoma and lung cancer — two of the most prevalent cancer types in Asia. This therapy is marketed in 47 countries and regions including the United States, European Union, China, and Japan, with over 60 indication-approval applications submitted to expand its global coverage.
BeOne’s integrated development approach combines robust R&D capabilities, a PoC-driven strategy and a wide portfolio of assets. With over 40 Phase 3-ready or registration-potential clinical trials and more than 40 R&D assets in clinical and commercialization stages, BeOne maintains leadership across multiple technology platforms, including multi-specific antibodies, chimeric degradation activating compounds (CDACs), and antibody-drug conjugates (ADCs).
Through the PoC strategy, BeOne concentrates on highly differentiated and promising molecule candidates. The company has successfully pushed through the clinical development for 20 drug molecules and obtained regulatory approvals across six continents, demonstrating its outstanding R&D efficiency and globalization strategy.
Globalization to Strengthen Sustainable Supply
BeOne has established three major R&D and manufacturing bases in the United States and China, encompassing the entire industry chain from research and development to manufacturing and commercialization. Notably, the Guangzhou campus spans 1.3 million ft2 and features advanced manufacturing capabilities to produce large-molecule drugs, serving as a core supply hub in the Greater Bay Area, including Hong Kong. This footprint ensures a stable drug supply and enhances accessibility for patients in the region.
As one of the world’s top 20 leading oncology patent holders3 and listed as one of the “World’s Top 10 Most Inventive Pharmaceutical Companies”4 by IDEA Pharma in 2025, BeOne will continue to devote its efforts to researching hematologic and solid tumors. Leveraging Hong Kong as a strategic bridge between Asia and the international community, BeOne is committed to accelerating the development and delivery of innovative therapies, collaboratively driving a new paradigm for cancer care regionally and globally.
Prof. Albert Yu, Chairman of Hong Kong Biotechnology Organization, remarked, “BeOne’s leadership in oncology is fully evident in its innovative drug development, globalization strategy, and significant improvements in quality of life for cancer patients locally and worldwide. Grounded in rigorous scientific research, BeOne aligns clinical needs with accessibility considerations across various markets to launch multiple self-developed innovative medicines to the global stage. The company’s efforts represent scientific excellence and a profound commitment to cancer patients, deserving of the Global Oncology Leadership Award.”
This press release contains forward-looking statements, and actual results may differ from those expressed or implied in these statements. All information provided herein is as of the date of this release, and unless required by law, BeOne has no obligation to update or revise any such information.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential benefits of sonrotoclax; BeOne’s expectations regarding sonrotoclax’s clinical development, regulatory milestones, submissions and approvals; BeOne’s plans to present the full data at an upcoming medical meeting; and BeOne’s plans, commitments, aspirations and goals under the caption “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.
[3] Top 50 Pharma: Oncology patent leaders 2024, Drug Discovery & Development
[4] 2025 Pharmaceutical Innovation and Invention Index, IDEA Pharma
Hashtag: #BeOneMedicines
The issuer is solely responsible for the content of this announcement.
About BeOne Medicines
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.
To learn more about BeOne, please visit 
www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.
About BIOHK Hong Kong International Biotechnology Conference & Exhibition
BIOHK Hong Kong International Biotechnology Conference & Exhibition is Asia’s premier biotechnology conference and exhibition. It aims to create a collaborative platform for industry leaders, innovators, and stakeholders to come together and drive the development of biotechnology. BIOHK is dedicated to advancing the biotech sector by not only providing a stage to showcase technological innovations but also offering a launchpad for companies seeking a market expansion to the Greater Bay Area and Mainland China. By combining educational seminars, strategic partnership opportunities, and governmental support, BIOHK empowers participants to foster significant advancements with profound impacts on global health and technology.
Media OutReach
Sun Group debuts at SITF 2026 with exclusive Phu Quoc flight deals and a fresh vision for Vietnam tourism
A special highlight is Sun Group’s unveiling of its new development vision for Phu Quoc in the lead‑up to APEC 2027, presented directly to Korean partners and visitors.
From the first day of the fair, Sun Group’s booth has welcomed a steady stream of visitors. Throughout the four-day event, the booth has organized B2B and B2C networking activities, customer consultations, and introductions to tourism, resort, and aviation products. Interactive programs, including mini-games, souvenir giveaways, and tailored offers for the Korean market, have kept the atmosphere lively for hours, with a continuous flow of engaged visitors.
During SITF (June 4–7), travelers have the opportunity to receive a 20% discount on the base fare when booking Sun PhuQuoc Airways tickets via the airline’s website or app. The offer applies to the Korean market for one‑way or round‑trip journeys from Korea to Phu Quoc. Limited to 200 Economy Class discount codes, it is valid for flights from June 15 to October 24, 2026 (excluding peak periods as defined by the airline).
Visitors also have the chance to win attractive prizes through booth activities, including free round‑trip air tickets on the Seoul–Phu Quoc route (ICN–PQC) and resort vouchers at hotels within Sun Group’s ecosystem.
By combining destination promotion with airline incentives, Sun Group aims to further encourage South Korean tourists to choose Vietnam for their upcoming holidays, especially Phu Quoc, which is entering a new era of large‑scale investments in projects, products, and experiences all aimed at APEC 2027.
Hashtag: #SunGroup
The issuer is solely responsible for the content of this announcement.
About Sun Group
Vietnam’s leading private economic group, Sun Group operates an integrated ecosystem spanning tourism, entertainment, hospitality, real estate, infrastructure, and aviation. Guided by the mission “Enhancing the beauty of the lands,” the Group shapes iconic destinations nationwide through its Sun World entertainment brand. In the aviation sector, Sun Group develops a hub-and-spoke model anchored by Phu Quoc, driven by strategic airport investments and Sun PhuQuoc Airways.
Media OutReach
Technology + Scenario + Supply Chain = A New Benchmark for Regional Zero-Carbon Smart Transportation
Wing Kai New Energy X QIJI Energy X C&D Hi-Tech
HONG KONG SAR – Media OutReach Newswire – 5 June 2026 – The 19th (2026) International Photovoltaic Power Generation and Smart Energy Exhibition & Conference (SNEC 2026) was grandly held from June 3 to 5, 2026, at the National Exhibition and Convention Center (Shanghai). Attracting over 3,000 exhibitors from 95 countries worldwide, the event stands as the largest and most influential professional grand gathering for the photovoltaic and energy storage sectors across Asia and globally.
During the exhibition, Mr. Yiu Wang Lee, Chairman of the Board of Wing Lee Development Construction Holdings Limited (“Wing Lee” or the “Group”, stock code: 9639.HK); Mr. Cai Huihui, General Manager of Wing Kai New Energy Technology Co., Limited (“Wing Kai New Energy”); Mr. Wang Yi, Key Account Manager of QIJI Energy; Mr. Xu Jun, Overseas Energy Storage Commercial Director of Contemporary Amperex Technology Co., Limited (CATL); and Mr. You Yuxian, ASEAN Regional Energy Storage Sales Director of CATL, jointly visited the exhibition booth of C&D Hi-Tech. The delegation engaged in in-depth discussions with the team led by General Manager Mr. Zhan Shengli, focusing on battery swapping station projects in Hong Kong and Southeast Asia. By integrating multi-party resources, the teams successfully finalized and signed a Strategic Cooperation Agreement.
Through this signing, the three parties will join forces to address and resolve the industry pain points of overseas markets regarding regulatory compliance, engineering infrastructure, and supply chain coordination. The collaboration represents a deep integration of QIJI Energy’s cutting-edge battery swapping solutions, Wing Kai New Energy’s localized infrastructure and operational capabilities across Hong Kong and Shenzhen, and C&D Hi-Tech’s robust global resource allocation strengths. Moving from single-project development to an ecosystem of mutual win-win, this partnership will significantly enhance the delivery efficiency of green energy across Hong Kong, Macau, and the Southeast Asian region, setting a brand-new benchmark for regional zero-carbon smart transportation.
As a subsidiary of Wing Lee, Wing Kai New Energy has been rooted in Hong Kong since its inception while radiating its presence globally, deeply cultivating sustainable clean energy solutions. Addressing the acute pain points in the Greater Bay Area and Southeast Asian markets, where rapid fluctuations in energy prices have led to surging cost pressures for logistics distribution enterprises, Wing Kai New Energy will focus on urban distribution logistics battery swapping businesses in the future. The company plans to integrate site resources, infrastructure, and operations to fill the gap in regional infrastructure. We firmly believe that this cooperation will effectively bridge the cross-border green energy eco-link, accelerate the construction of a green energy service network, and contribute solidly to the realization of the “dual carbon” goals. Meanwhile, we sincerely invite more partners to join the Zero-Carbon Smart Alliance to jointly advance sustainable development.
Hashtag: #WingLee
The issuer is solely responsible for the content of this announcement.
About Wing Lee Development Construction Holdings Limited
Deeply rooted in Hong Kong, Wing Lee is an established contractor engaged in civil engineering, electrical and mechanical engineering, and new energy businesses, and has participated in various large-scale landmark projects in Hong Kong. The Group’s civil engineering business specialized in site formation waterworks as well as road and drainage works, while its electrical and mechanical engineering business specializes in power system-related projects and emergency maintenance works. In recent years, the Group has actively expanded into the new energy sector, undertaking solar photovoltaic projects, distributing various electric commercial vehicles and electric construction machinery, and engaging in the construction and subsequent maintenance of charging piles, battery swapping, recycling, and energy storage businesses. In 2025, Wing Lee Construction, together with SANY Group Co., Ltd. and CATL, among other industry giants, founded the “Zero-Carbon Smart Alliance” to develop full-industry-chain solutions for photovoltaics, energy storage, charging and battery swapping, and smart applications in green transportation.
The delegation of over 70 business and institutional leaders from Hong Kong and the Chinese Mainland is the largest and most diverse overseas mission led by the current term of the HKSAR Government so far.
Speaking to the media in Uzbekistan yesterday (June 4), Mr Lee set out the three main objectives of the visit: further explore emerging markets and lay the foundation for long-term economic and trade development; strengthen government-to-government (G2G) relationships and promote closer bilateral co-operation; and build a “hub-to-hub” model of co-operation.
He said the visit had been successful, yielding achievements in eight areas, including:
- Establishing high-level contacts and ties between the HKSAR Government and the Governments of Kazakhstan and Uzbekistan, and reaching consensus on co-operation in multiple areas;
- A total of 96 co-operation agreements and memoranda of understanding (MoUs) were reached during the visit (61 with Kazakhstan, 35 with Uzbekistan), involving specific amounts exceeding US$1.65 billion in total;
- The governments agreed to commence bilateral discussions on agreements in various areas;
- Deepening project matching and research collaboration between Hong Kong and Central Asian region in areas including finance, innovation and technology (I&T), and aviation;
- Demonstrating Hong Kong’s effective role as a platform for going global and achieving substantial results, with Hong Kong and Mainland enterprises joining forces in tapping new markets and bringing synergistic advantages into full play;
- Facilitating more convenient people-to-people exchanges by promoting direct flights, aviation and transport co-operation, and extensions to the mutual visa-free period;
- Promoting exchanges in education, talent and culture to further deepen people-to-people bonds; and
- Advancing a hub-to-hub co-operation model to open up broader room for co-operation between Hong Kong and the Central Asian region.
While in Tashkent (June 3-5), Mr Lee met with local leaders, government officials and business representatives to deepen co-operation between Hong Kong and Uzbekistan in areas including trade, investment, finance, I&T, and people-to-people exchanges.
Mr Lee held meetings with the President of Uzbekistan, Shavkat Miromonovich Mirziyoyev, his Advisor on Strategic Development, Sardor Umurzakov, the Prime Minister, Abdulla Nigmatovich Aripov, as well as the Deputy Prime Minister, Jamshid Khodjayev, to exchange views on furthering mutual co-operation.
Mr Lee highlighted that under the “one country, two systems” principle, Hong Kong enjoys both the China advantage and the global advantage. He said that Hong Kong would continue to play its roles as a “super connector” and a “super value-adder” to further deepen co-operation and exchanges with Uzbekistan on various fronts in line with Uzbekistan’s goal of achieving high-quality development.
Earlier (June 3), Mr Lee met with the Minister of Foreign Affairs of Uzbekistan, Bakhtiyor Saidov, after which they jointly witnessed an exchange of notes between the two places on a mutual visa-free arrangement, which would allow a visa-free period of 30 days for visitors from both sides.
“Moreover, we are glad to have initialed the Air Services Agreement with Uzbekistan, and look forward to launching direct passenger flights between the two places soon,” Mr Lee said, during a high-level business dinner (June 4). The Chief Executive pointed out that Hong Kong and Uzbekistan are important trade and investment gateways to their respective regions – the Asia-Pacific and Central Asia.
“It helps that we are all believers in the Belt and Road (B&R) Initiative, a modern expression of the ancient Silk Road spirit,” Mr Lee said. “Today, China is Uzbekistan’s largest trading partner, and the two countries work closely on major infrastructure and connectivity projects that are revitalising the Silk Road. Hong Kong is a pivotal player in the B&R Initiative, thanks to our world-class professional and financial services expertise.”
The delegation also toured the IT Park Uzbekistan and the Center for Islamic Civilization before concluding its visit in Tashkent.
Hashtag: #HongKong #BrandHongKong #CentralAsia #Kazakhstan #Uzbekistan
https://www.brandhk.gov.hk/
https://www.linkedin.com/company/brand-hong-kong/
https://x.com/Brand_HK/
https://www.facebook.com/brandhk.isd
https://www.instagram.com/brandhongkong
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn